Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of subcutaneous guselkumab in participants with active psoriatic arthritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthritis, Psoriatic | Phase 3 | Status: COMPLETED | Results posted: 2020-11-05